On Friday, Immunome Inc (NASDAQ: IMNM) opened lower -5.54% from the last session, before settling in for the closing price of $8.66. Price fluctuations for IMNM have ranged from $8.30 to $26.70 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -7.10%. Company’s average yearly earnings per share was noted 44.60% at the time writing. With a float of $75.59 million, this company’s outstanding shares have now reached $84.67 million.
Let’s determine the extent of company efficiency that accounts for 118 employees. In terms of profitability, gross margin is 89.65%, operating margin of -3382.37%, and the pretax margin is -3240.38%.
Immunome Inc (IMNM) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Immunome Inc is 13.07%, while institutional ownership is 63.08%. The most recent insider transaction that took place on Jan 31 ’25, was worth 1,162,500. In this transaction President and CEO of this company bought 150,000 shares at a rate of $7.75, taking the stock ownership to the 669,636 shares. Before that another transaction happened on Nov 21 ’24, when Company’s President and CEO bought 66,057 for $9.54, making the entire transaction worth $630,263. This insider now owns 485,693 shares in total.
Immunome Inc (IMNM) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.61 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 44.60% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.81% during the next five years compared to -38.15% drop over the previous five years of trading.
Immunome Inc (NASDAQ: IMNM) Trading Performance Indicators
Check out the current performance indicators for Immunome Inc (IMNM). In the past quarter, the stock posted a quick ratio of 4.08. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 78.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.18, a number that is poised to hit -0.67 in the next quarter and is forecasted to reach -2.96 in one year’s time.
Technical Analysis of Immunome Inc (IMNM)
Looking closely at Immunome Inc (NASDAQ: IMNM), its last 5-days average volume was 1.36 million, which is a jump from its year-to-date volume of 0.94 million. As of the previous 9 days, the stock’s Stochastic %D was 17.49%. Additionally, its Average True Range was 0.64.
During the past 100 days, Immunome Inc’s (IMNM) raw stochastic average was set at 0.14%, which indicates a significant decrease from 0.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.75% in the past 14 days, which was lower than the 76.22% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.77, while its 200-day Moving Average is $12.33. However, in the short run, Immunome Inc’s stock first resistance to watch stands at $8.56. Second resistance stands at $8.93. The third major resistance level sits at $9.13. If the price goes on to break the first support level at $7.99, it is likely to go to the next support level at $7.79. Now, if the price goes above the second support level, the third support stands at $7.42.
Immunome Inc (NASDAQ: IMNM) Key Stats
There are currently 86,951K shares outstanding in the company with a market cap of 711.26 million. Presently, the company’s annual sales total 14,020 K according to its annual income of -106,810 K. Last quarter, the company’s sales amounted to 2,910 K and its income totaled -47,100 K.
